Press Releases


First contract award from new Imaging Master Vendor Agreement with top 5 global CRO

IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been awarded a new contract with a value of more than >$750k over 2 years for advanced neuroimaging solutions by a top 5 global Clinical Research Organization ("CRO") to support its sponsor's Phase II Alzheimer's disease clinical trial.

Read more

Phase II Huntington's disease contract award with new client worth >$500K

IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been awarded a contract by a new US biopharmaceutical client to support its Phase II Huntington's disease (HD) clinical trial. HD is a rare condition of the nervous system that impacts the way people think, behave, and move.

Read more

Phase I Multiple System Atrophy contract award worth >$500k

IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been awarded a contract by a new biopharmaceutical client to support its Phase I multiple system atrophy clinical trial.

Read more

Trading Update

Expected FY21 financial performance of £8. 7m revenues and c. £1. 2m EBITDA thereby maintaining strong EBITDA margin performance. IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces a trading update, confirming that, despite a challenging business environment, it expects to deliver £8.

Read more

Half yearly report to 31 March 2021

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces its unaudited interim results for the six months ended 31 March 2021. Financial highlights: · Reported revenues of £4. 9 million for the six months to 31 March 2021 (H1 2020: £4.

Read more

Phase II Alzheimer’s disease contract award worth >£1m

IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been awarded an expansion contract by a current biopharmaceutical client to support the company’s Phase II Alzheimer’s disease clinical trial.

Read more

Contract win for new neuroinflammatory disorder

Contract extends IXICO’s CNS franchise to include a further new disease indication IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been selected by a current biopharmaceutical client to provide neuroimaging services for a Phase III clinical trial.

Read more

Contract win for new stroke study

New therapeutic area, broadening IXICO’s neurological footprint IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has executed a contract to provide neuroimaging services for a new clinical trial for acute ischemic stroke with its largest pharma client.

Read more

1-8 of 51 results